Targeted Investors Identify allied funding partners and strategic investors tied to synthetic biology and biotechnology research who previously invested in RootPath or similar platforms, to pursue co-investment, collaboration, or channel partnerships that can accelerate go-to-market efforts.

Clinical Translation Leverage RootPath’s high-throughput gene function interrogation capabilities to approach biotech and pharma companies focusing on cell therapy, immunotherapy, and precision medicine, offering accelerated target validation and pipeline enrichment.

SMB to Enterprise Position RootPath as an accessible, scalable DNA fragment assembly and functional readout solution for mid-market and university-affiliated biotech labs that need greater throughput at a lower cost, expanding customer segments beyond large pharma.

Strategic Partnerships Explore partnerships with contract research organizations, CROs, and academic consortia that require rapid gene function screening, enabling joint go-to-market packages and bundled services.

Global Expansion Capitalize on prior global funding activity by tailoring regional market entries in Asia and Europe, aligning with potential co-investors and regional biotech clusters to accelerate adoption and scale.